Could ozempic stop pancreatitis from coming back?

NCT ID NCT07617155

Not yet recruiting Prevention Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether semaglutide (Ozempic/Wegovy) can prevent repeat episodes of acute pancreatitis caused by very high triglycerides. About 396 adults who recently had such an attack will receive either semaglutide injections or a placebo for 18 months, alongside standard care. Researchers will track how many have another pancreatitis episode and whether their triglyceride levels improve.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Semaglutide (Ozempic, Wegovy)
What this could lead to: If it works, this could offer a new way to prevent repeat episodes of severe pancreatitis in people with very high triglycerides.
What could go wrong: This is a Phase 4 trial that hasn't started yet. The drug may not reduce pancreatitis risk, and side effects like nausea or rare gallbladder issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTRIGLYCERIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic pancreatitis hypertriglyceridemia pancreatitis recurrent acute pancreatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTRIGLYCERIDEMIA HYPERTRIGLYCERIDEMIA INDUCED ACUTE PANCREATITIS PANCREATITIS RELAPSING RECURRENT ACUTE PANCREATITIS

Contacts and locations

Locations

Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.